Duffy null status predicts severe neutropenia after ciltacabtagene autoleucel but not other BCMA therapies in myeloma. // Blood Immunology & Cellular Therapy. – URL: https://www.sciencedirect.com/science/article/pii/S3050597626000722?dgcid=rss_sd_all
Duffy null status predicts severe neutropenia after ciltacabtagene autoleucel but not other BCMA therapies in myeloma. Blood Immunology & Cellular Therapy. https://www.sciencedirect.com/science/article/pii/S3050597626000722?dgcid=rss_sd_all
“Duffy null status predicts severe neutropenia after ciltacabtagene autoleucel but not other BCMA therapies in myeloma.” Blood Immunology & Cellular Therapy.
@article{article38278,
title = {Duffy null status predicts severe neutropenia after ciltacabtagene autoleucel but not other BCMA therapies in myeloma},
journal = {Blood Immunology \& Cellular Therapy},
url = {https://www.sciencedirect.com/science/article/pii/S3050597626000722?dgcid=rss_sd_all}
}